XTACY Therapeutics
Debt Settlement Update

Vancouver: June 13, 2024 – Xtacy Therapeutics Corp. (CSE: XTCY) (Frankfurt: TT5) (OTC: XTCYF) ("the Company) the Company wishes to amend the detail as announced May 13, 2024, regarding its debt Settlements. The Company will issue an aggregate of 3,580,500 common shares (the "Settlement Shares") to certain creditors in exchange for outstanding accounts payable (the "Shares for Debt Transaction") in the aggregate amount of CA$179,025 (the "Debt") owing to certain creditors (the "Creditors").

The Settlement Shares will be issued at a price of $0.05, in accordance with the policies of the Canadian Securities Exchange (the "CSE"). As previously noted the Company feels that issuing the Shares for Debt will put the Company in a better financial position by reducing its existing liabilities. The securities issued in connection with the Debt Settlement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. Pursuant to the policies of the Canadian Securities Exchange, the Debt Settlement will close five business days from the date of this press release.

About Xtacy Therapeutics Corp. :

Xtacy is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.

For further information visit website:
 www.xtacytherapeutics.com

Or Contact Meris Kott CEO email to info@xtacytherapeutics.com (604) 484-0355

Further information about the Company is available on www.SEDARplus.com under the Company's profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.